...2, 2019 doi:10.1124/jpet.118.252668 CONTACT: Norikazu Kiguchi, Wakayama Medical University, Wakayama, Japan email: kiguchi@wakayama-med.ac.jp Claire Quang Wakayama Medical University Nicotinic acetylcholine receptor alpha(4)beta(2) Pain Diabetes Wakayama...

...treat ADHD. Attenua also purchased discontinued candidates TC-6987, a CHRNA7 modulator, and TC-6683, a neuronal nicotinic acetylcholine receptor alpha(4)beta(2)...
...13, 2016) . Attenua Inc., Mountain View, Calif. Jaime De Leon Attenua Inc. Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Nicotinic acetylcholine receptor alpha(4)beta(2) ATA-101 TC-5619 TC-6683 TC-6987...

...treat ADHD. Attenua also purchased discontinued candidates TC-6987, a CHRNA7 modulator, and TC-6683, a neuronal nicotinic acetylcholine receptor alpha(4)beta(2)...
...2016 (see BioCentury Extra, June 9, 2016) . Jaime De Leon Attenua Inc. Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Nicotinic acetylcholine receptor alpha(4)beta(2) ATA-101 TC-5619 TC-6683 TC-6987...

...granted AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) rights to develop and commercialize TC-6683, a neuronal nicotinic acetylcholine receptor alpha(4)beta(2)...

...NASDAQ:TRGT), Winston-Salem, N.C. Product: TC-6499 Business: Gastrointestinal Molecular target: Nicotinic acetylcholine receptor alpha(3)beta(4) ; Nicotinic acetylcholine receptor alpha(4)beta(2)...

...and depression vs. other smoking-cessation products (see BioCentury, Nov. 7, 2011). Pfizer markets the selective nicotinic acetylcholine receptor alpha(4)beta(2)...

...gained rights to develop and commercialize AZD1446 for any indication. AZD1446 and AZD3480 are neuronal nicotinic acetylcholine receptor alpha(4)beta(2)...